First-in-human exploratory trial assessing safety, feasibility, and efficacy of artificial protein (silk-elastin) in promoting healing in patients with meniscus injuries

被引:0
|
作者
Ishikawa, Masakazu [1 ,2 ,5 ]
Tsuji, Shunya [2 ]
Kamei, Goki [2 ]
Nakata, Kyohei [2 ]
Nekomoto, Akinori [2 ]
Hashiguchi, Naofumi [2 ]
Nakasa, Tomoyuki [2 ]
Nakamae, Atsuo [2 ]
Kamei, Naosuke [2 ]
Inoue, Keiichiro [3 ]
Kawabata, Shingo [3 ]
Ueda, Keiko [4 ]
Adachi, Nobuo [2 ]
机构
[1] Kagawa Univ, Fac Med, Dept Orthoped Surg, Takamatsu, Kagawa, Japan
[2] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Orthoped Surg, Hiroshima, Japan
[3] Sanyo Chem Ind, Kyoto, Japan
[4] Trarnslat Res Ctr Med Innovat, Kobe, Hyogo, Japan
[5] Kagawa Univ, Fac Med, Dept Orthoped Surg, 1750-1 Ikenobe,Miki Cho, Takamatsu, Kagawa 7610793, Japan
来源
SCIENTIFIC REPORTS | 2025年 / 15卷 / 01期
关键词
Meniscus tear; Arthroscopic meniscus repair; Artificial protein; Silk-elastin; Needle arthroscope; Knee osteoarthritis; PLATELET-RICH PLASMA; ARTHROSCOPIC EVALUATION; NEEDLE ARTHROSCOPY; LATERAL MENISCUS; REPAIR; TEARS; AUGMENTATION; KNEES; COST;
D O I
10.1038/s41598-025-88616-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Meniscal tears, especially those in avascular regions, pose a significant risk for osteoarthritis if repair fails. While meniscal repair is the preferred method for preserving knee function, it often has a high failure rate in avascular zones. This study aimed to evaluate the safety and potential efficacy of silk-elastin (SE), an artificial protein with wound-healing properties, for enhancing meniscal repair. Eight patients with meniscal tears in avascular areas underwent arthroscopic repair followed by SE application, including cases of lateral and medial tears, discoid lateral meniscus, and bucket-handle tears. No adverse events or reactions were attributed to SE. At 3 months post-surgery, clinical outcomes and repair sites were evaluated using MRI and arthroscopy. Significant improvements were observed in Lysholm and visual analog scale scores (P < 0.05), with the knee injury and osteoarthritis outcome scores showing significant improvement in the symptom subscale. MRI findings indicated one patient with grade 1 healing, three with grade 2, and four with grade 3 (unhealed). Arthroscopically, six patients demonstrated completely healed menisci, while two showed incomplete healing; none were classified as "unhealed." These findings suggest that SE is safe and may support meniscal healing in avascular zones, indicating its potential to improve repair outcomes.
引用
收藏
页数:13
相关论文
共 29 条
  • [1] Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial
    Siebenhaar, Frank
    Altrichter, Sabine
    Bonnekoh, Hanna
    Hawro, Tomasz
    Hawro, Marlena
    Michaelis, Edward G.
    Kantor, Andrea M.
    Chang, Alan T.
    Youngblood, Bradford A.
    Singh, Bhupinder
    Rasmussen, Henrik S.
    Maurer, Marcus
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 189 (05) : 511 - 519
  • [2] Safety and Efficacy of First-in-human Clinical Trial of Intrathecal Transplantation of Human Astrocytes (AstroRx) Derived from hESC in ALS Patients
    Izrael, Michal
    Gotkine, Marc
    Lerner, Yossef
    Slutsky, Guy Shalom
    Chebath, Judith
    Caraco, Yoseph
    Ben-Hur, Tamir
    Hasson, Arik
    Sonnenfeld, Tehila
    Revel, Michel
    MUSCLE & NERVE, 2022, 66 : S48 - S48
  • [3] Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors
    Ponomarenko, Dmitry M.
    Klimova, Irina D.
    Chapygina, Yulia A.
    Dvornichenko, Viktoria V.
    Zhukova, Natalia V.
    Orlova, Rashida V.
    Manikhas, Georgy M.
    Zyryanov, Alexandr V.
    Burkhanova, Lilya A.
    Badrtdinova, Irina I.
    Oshchepkov, Basile N.
    Filippova, Elena V.
    Orlov, Sergei V.
    Kolesnikov, Sergei I.
    Sufianov, Albert A.
    Baum, Svetlana R.
    Zaitzeva, Olga Y.
    Komissarov, Andrey B.
    Grudinin, Mikhail P.
    Kiselev, Oleg I.
    Tsyb, Anatoly F.
    Venanzi, Franco
    Shcherbinina, Vita
    Chursov, Andrey
    Gabai, Vladimir L.
    Shneider, Alexander M.
    ONCOTARGET, 2017, 8 (32) : 53730 - 53739
  • [4] Safety and efficacy of first-in-human intrathecal transplantation of human astrocytes (AstroRx®) in ALS patients: Phase I/IIA clinical trial results
    Izrael, Michal
    Gotkine, Marc
    Slutsky, Guy
    Lerner, Yossef
    Chebath, Judith
    Kuperstein, Graciela
    Estrin, Elena
    Caraco, Yoseph
    Ben-Hur, Tamir
    Hasson, Arik
    Sonnefeld, Tehila
    Stark, Yafit
    Revel, Ariel
    Revel, Michel
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429 : 256 - 256
  • [5] Personalized immunotherapy with encapsulated cell technology: Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors
    Fernandez, E.
    Vernet, R.
    Charrier, E.
    Migliorini, D. M.
    Urwyler, M.
    Belkouch, M-C.
    Von Rohr, O.
    Saingier, V.
    Ancrenaz, V.
    Grandjean, N.
    Lafferma, E.
    Lavalliere, E.
    Rubin, O.
    Villard, J.
    Grogg, J. N.
    Mach, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S891 - S891
  • [6] First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial
    Verdijk, Pauline
    van der Plas, Johan L.
    van Brummelen, Emilie M. J.
    Jeeninga, Rienk E.
    de Haan, Cornelis A. M.
    Roestenberg, Meta
    Burggraaf, Jacobus
    Kamerling, Ingrid M. C.
    VACCINE, 2020, 38 (39) : 6088 - 6095
  • [7] Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
    Tsimberidou, Apostolia M.
    Guenther, Kerstin
    Andersson, Borje S.
    Mendrzyk, Regina
    Alpert, Amir
    Wagner, Claudia
    Nowak, Anna
    Aslan, Katrin
    Satelli, Arun
    Richter, Fabian
    Kuttruff-Coqui, Sabrina
    Schoor, Oliver
    Fritsche, Jens
    Coughlin, Zoe
    Mohamed, Ali S.
    Sieger, Kerry
    Norris, Becky
    Ort, Rita
    Beck, Jennifer
    Vo, Henry Hiep
    Hoffgaard, Franziska
    Ruh, Manuel
    Backert, Linus
    Wistuba, Ignacio I.
    Fuhrmann, David
    Ibrahim, Nuhad K.
    Morris, Van Karlyle
    Kee, Bryan K.
    Halperin, Daniel M.
    Nogueras-Gonzalez, Graciela M.
    Kebriaei, Partow
    Shpall, Elizabeth J.
    Vining, David
    Hwu, Patrick
    Singh, Harpreet
    Reinhardt, Carsten
    Britten, Cedrik M.
    Hilf, Norbert
    Weinschenk, Toni
    Maurer, Dominik
    Walter, Steffen
    CANCER IMMUNOLOGY RESEARCH, 2023, 11 (07) : 925 - 945
  • [8] A FIRST-IN-HUMAN FEASIBILITY STUDY TO EVALUATE THE SAFETY OF SELECTIVE YTTRIUM-90 ENDOVASCULAR RADIOTHERAPY IN PATIENTS WITH RECURRENT GBM: INTERIM RESULTS FROM THE FRONTIER TRIAL
    Mouli, Samdeep
    Ansari, Sameer
    Middlebrooks, Erik
    Boockvar, John
    Weinstein, Jonathan
    Serulle, Yafell
    Butowski, Nicholas
    Narsinh, Kazim
    Kennedy, Paul
    Eldridge, Amanda
    Basarabescu, Franco
    Elahi-Gedwillo, Kianna
    Salem, Riad
    Stupp, Roger
    NEURO-ONCOLOGY, 2024, 26
  • [9] CLINICAL SAFETY AND PROTECTIVE EFFICACY AFTER IMMUNIZATION WITH GENETICALLY MODIFIED PLASMODIUM BERGHEI SPOROZOITES EXPRESSING P. FALCIPARUM CIRCUMSPOROZOITE PROTEIN IN A FIRST-IN-HUMAN PHASE1/2A TRIAL
    Mendes, Antonio M.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2019, 101 : 528 - 528
  • [10] SAFETY AND PRELIMINARY EFFICACY AND PHARMACOKINETICS OF INTRAPERITONEAL VS-01 INFUSIONS IN PATIENTS WITH DECOMPENSATED LIVER CIRRHOSIS: A FIRST-IN-HUMAN, OPEN-LABEL, PHASE 1b CLINICAL TRIAL
    Uschner, Frank Erhard
    Schulz, Martin
    Tyc, Olaf
    Ferstl, Philip
    Stoffers, Philipp
    Erasmus, Hans-Peter
    Masseli, Johannes
    Peiffer, Kai-Henrik
    Finkelmeier, Fabian
    Pathil, Anita
    Bojunga, Joerg
    Biguenet, Sophie
    Zeuzem, Stefan
    Kabbaj, Meriam
    Trebicka, Jonel
    HEPATOLOGY, 2021, 74 : 139A - 139A